The advantage is that the existence of available P2Y12R antagonists such as clopidogrel and ticagrelor, with an affordable cost and for use in patients presenting platelet disorders, may contribute to treatment accessibility through the use of drug repositioning as an interesting tool to cancer therapy. Here, P2RY12 is linked to blood platelet disease.